

January 16, 2018

NeutriSci International Inc. (TSXV: NU)

Healthcare | Drugs - Specialty

- NeutriSci announced that it entered an R&D Memorandum of Understanding (MOU) with Scientus Pharma Inc. to distribute a medical cannabinoid product through existing Canadian retail distribution networks.
- Glen Rehman – previously President of NU – was promoted to CEO and NeutriSci completed a non-brokered private placement of ~\$500k.
- NeutriSci announced a one-year sponsorship agreement with Genie Bouchard, an international tennis star from Montreal, Quebec.

Company Description

NeutriSci International Inc. ("NU") develops, markets, and distributes clinically-proven nutraceutical products in Canada. It focuses on the development of these products in areas including heart and cholesterol health, sleep deprivation, immune defense, and men's prostate and sexual health. NU's website is www.neutrisci.com, and it is headquartered in Calgary, Canada.

Key Data

52-Week Range (\$)	0.35 – 0.06
Shares Outstanding (mn)	92.6
Market Cap (\$mn)	21.3
3-Mo. Avg Volume (mn)	1.1
Total Cash (\$mn)	0.032
Total Debt (\$mn)	0.119

Key Financials (\$mn)

	FY14A	FY15A	FY16A
Revenue	0.026	0.024	0.125
EBIT	-4.270	-3.727	-2.586
EBITDA	-4.255	-3.716	-2.576
Earnings	-7.549	-3.739	-2.564
CFF	2.408	2.300	1.764

One-Year Price and Volume History



NeutriSci Entered R&D MOU with Scientus Pharma

On January 8, 2018, NeutriSci announced that it entered an R&D Memorandum of Understanding (MOU) with Scientus Pharma Inc. The companies plan to distribute a medical cannabinoid product through existing Canadian retail distribution networks. This product will be developed, tested and produced with the shared technologies of the companies. Specifically, NeutriSci will fund Scientus' research on NU's products in combination with a multitude of cannabinoids. Potential preclinical and clinical trials may be co-funded, with both companies having rights for product development and testing.

[Scientus Pharma](#) is one of the few vertically-integrated biopharmaceutical Licensed Dealers under the Narcotics Control Regulations under Canada's Controlled Drugs and Substances Act. This license permits the company to wholesale, purchase, process and sell cannabinoid derivatives with other Licensed Dealers and in international markets. It focuses on the development and commercialization of pharmaceutical-grade medicinal cannabinoid derivative products. Additionally, Health Canada recently gave Scientus its Access to Cannabis for Medical Purposes Regulations ("ACMPR") license.

Capital Raise & Appointment of Glen Rehman as CEO

Glen Rehman – previously President of NU – was promoted to CEO and will be replacing Scott Ackerman, who resigned from the position. Mr. Rehman was President for ~3 years and has over 20 years' experience in banking, retail, operations, and management. Before joining NU, Mr. Rehman was COO of Cineplex Media, formerly Vautcom Media.

Also in December 2017, NeutriSci completed a non-brokered private placement of ~\$500k. ~5.5mn units were sold at \$0.09, with each unit consisting of one common share and one half of one common share purchase warrant. A holder can purchase one common share with each full warrant at a price of \$0.15 until June 6, 2019.

Proceeds plan to largely be used for marketing and advertising of one of its lead products, Neuenergy, which is an energy tab designed to deliver mental clarity and a focus enhancement. The product does not contain sugar, calories or the "crash" commonly associated with competitor products.



Sponsorship Agreement with Tennis Star Genie Bouchard

NU announced a one-year sponsorship agreement with Genie Bouchard, an international tennis star from Montreal, Quebec. Bouchard's brand is associated with active and healthy living, which aligns well with NeutriSci's branding. The company plans to include Bouchard in key marketing efforts for its Neuenergy product, such as advertising, retail activation, and experiential events.

JGR Capital Information

Headquarter Address

[845 Third Avenue, Fl 6](#)
[New York, NY 10022](#)

Contact

research@jgrcap.com
[\(646\) 688.3131](tel:(646)688.3131)

Disclosure

This report contains forward-looking statements, which involve risks and uncertainties. Actual results may differ significantly from such forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in the "Risk Factors" section in the SEC filings available in electronic format through SEC Edgar filings at www.SEC.gov.

The research analysts principally responsible for this research preparation do not receive compensation that is based upon any specific investment banking services or recommendations and can be compensated based on factors relating to the overall profitability of JGR Capital ("firm"). As of the date of research distribution, neither the firm nor the principal research analysts beneficially own 1% or more of any class of common equity securities for this issuer (including, without limitation, any option, right, warrant, future, long or short position).

The securities of the issuer(s) discussed in this research may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This research does not constitute a personal trading recommendation or take into account the particular investment objectives, financial situation or needs of an individual reader of this report, and does not provide all of the pertinent information to make an investment decision.

JGR Capital does not provide investment banking services nor has it received compensation for investment banking services from the issuers covered in this research content. The firm does not make a market in the issuer's securities. It has received compensation from the issuer for providing non-investment banking services to this issuer. The non-investment banking services provided to the issuer includes investor relations' advisory and services, production of this research content, comprehensive reporting analytics, and financial analysis. The fees for these services vary on a per-client basis and are subject to the amount and category of provided services. Firm analysts and members of the research production team are prohibited from holding or trading securities in the issuer.

Additional information is available upon request. JGR Capital's research contents are based on data obtained from sources that it believes to be reliable and does not purport to be a complete statement of all material factors. This report is for informational purposes and is not a solicitation of orders to purchase or sell securities. No part of this material may be copied, photocopied or duplicated in any form or by any means, or redistributed without prior written consent from JGR Capital. All rights reserved.